Nothing Special   »   [go: up one dir, main page]
create a website
Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs.. (1999). Rizzo, John.
In: Journal of Law and Economics.
RePEc:ucp:jlawec:v:42:y:1999:i:1:p:89-116.

Full description at Econpapers || Download paper

Cited: 75

Citations received by this document

Cites: 32

References cited by this document

Cocites: 31

Documents which have cited the same bibliography

Coauthors: 0

Authors who have wrote about the same topic

Citations

Citations received by this document

  1. Evolving Market Boundaries and Competition Policy Enforcement in the Pharmaceutical Industry. (2023). Ornaghi, Carmine ; Siotis, Georges ; de Moura, Micael Castanheira.
    In: ULB Institutional Repository.
    RePEc:ulb:ulbeco:2013/353440.

    Full description at Econpapers || Download paper

  2. Evolving market boundaries and competition policy enforcement in the pharmaceutical industry. (2023). Castanheira, Micael ; Ornaghi, Carmine ; Siotis, Georges.
    In: European Journal of Law and Economics.
    RePEc:kap:ejlwec:v:55:y:2023:i:2:d:10.1007_s10657-022-09760-7.

    Full description at Econpapers || Download paper

  3. A dynamic model of price competition and promotion in prescription drug markets. (2022). Roy, Abhik.
    In: Marketing Letters.
    RePEc:kap:mktlet:v:33:y:2022:i:4:d:10.1007_s11002-022-09632-9.

    Full description at Econpapers || Download paper

  4. Regulating Conflicts of Interest in Medicine Through Public Disclosure: Evidence from a Physician Payments Sunshine Law. (2022). Larkin, Ian ; Chao, Matthew.
    In: Management Science.
    RePEc:inm:ormnsc:v:68:y:2022:i:2:p:1078-1094.

    Full description at Econpapers || Download paper

  5. Advertising persuasion in dual markets. (2021). Keswani, Aneel ; Vakratsas, Demetrios ; Stolin, David.
    In: Managerial and Decision Economics.
    RePEc:wly:mgtdec:v:42:y:2021:i:1:p:239-245.

    Full description at Econpapers || Download paper

  6. Pharmaceutical opioid marketing and physician prescribing behavior. (2021). Beilfuss, Svetlana ; Linde, Sebastian.
    In: Health Economics.
    RePEc:wly:hlthec:v:30:y:2021:i:12:p:3159-3185.

    Full description at Econpapers || Download paper

  7. Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling. (2021). Chatterjee, Chirantan ; Yan, Xin ; Higgins, Matthew J.
    In: Research Policy.
    RePEc:eee:respol:v:50:y:2021:i:1:s0048733320302018.

    Full description at Econpapers || Download paper

  8. Market Definition and Competition Policy Enforcement in the Pharmaceutical Industry. (2020). Castanheira, Micael ; de Moura, Micael Castanheira ; Ornaghi, Carmine ; Siotis, Georges.
    In: Working Papers ECARES.
    RePEc:eca:wpaper:2013/315066.

    Full description at Econpapers || Download paper

  9. How Much is Too Much? The Effect of Offline Call Intensity on Online Purchase of Digital Services. (2020). Yao, Yuliang ; Zhang, Xingyue.
    In: Production and Operations Management.
    RePEc:bla:popmgt:v:29:y:2020:i:3:p:509-525.

    Full description at Econpapers || Download paper

  10. The Unexpected Consequences of Generic Entry. (2019). Ornaghi, Carmine ; Castanheira, Micael ; Siotis, Georges ; de Moura, Micael Castanheira .
    In: ULB Institutional Repository.
    RePEc:ulb:ulbeco:2013/298643.

    Full description at Econpapers || Download paper

  11. The unexpected consequences of generic entry. (2019). Siotis, Georges ; Ornaghi, Carmine ; Castanheira, Micael.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:68:y:2019:i:c:s0167629618305332.

    Full description at Econpapers || Download paper

  12. The Unexpected Consequences of Generic Entry. (2019). Siotis, Georges ; Ornaghi, Carmine ; Castanheira, Micael.
    In: Working Papers ECARES.
    RePEc:eca:wpaper:2013/293928.

    Full description at Econpapers || Download paper

  13. Market definition in the pharmaceutical industry: a case of drugs hopping antitrust markets?. (2019). Siotis, Georges ; Ornaghi, Carmine ; Castanheira, Micael.
    In: CEPR Discussion Papers.
    RePEc:cpr:ceprdp:14035.

    Full description at Econpapers || Download paper

  14. Government health insurance and spatial peer effects: New evidence from India. (2018). Chatterjee, Chirantan ; Boregowda, P ; Sood, Neeraj ; Joshi, Radhika .
    In: Social Science & Medicine.
    RePEc:eee:socmed:v:196:y:2018:i:c:p:131-141.

    Full description at Econpapers || Download paper

  15. Effects of Physician‐directed Pharmaceutical Promotion on Prescription Behaviors: Longitudinal Evidence. (2017). Dave, Dhaval ; Datta, Anusua .
    In: Health Economics.
    RePEc:wly:hlthec:v:26:y:2017:i:4:p:450-468.

    Full description at Econpapers || Download paper

  16. Umbrella Branding in Pharmaceutical Markets. (2017). Suppliet, Moritz.
    In: Other publications TiSEM.
    RePEc:tiu:tiutis:be3f3c38-5e39-4a67-af57-820c14957e0b.

    Full description at Econpapers || Download paper

  17. Umbrella Branding in Pharmaceutical Markets. (2017). Suppliet, Moritz.
    In: Other publications TiSEM.
    RePEc:tiu:tiutis:6ee607fc-8602-4270-a076-3b0a18f71366.

    Full description at Econpapers || Download paper

  18. Umbrella Branding in Pharmaceutical Markets. (2017). Suppliet, Moritz.
    In: Discussion Paper.
    RePEc:tiu:tiutil:be3f3c38-5e39-4a67-af57-820c14957e0b.

    Full description at Econpapers || Download paper

  19. Umbrella Branding in Pharmaceutical Markets. (2017). Suppliet, Moritz.
    In: Discussion Paper.
    RePEc:tiu:tiucen:6ee607fc-8602-4270-a076-3b0a18f71366.

    Full description at Econpapers || Download paper

  20. The Unexpected Consequences of Asymmetric Competition. An Application to Big Pharma. (2017). Siotis, Georges ; Ornaghi, Carmine ; Castanheira, Micael ; de Frutos, Maria-Angeles .
    In: CEPR Discussion Papers.
    RePEc:cpr:ceprdp:11813.

    Full description at Econpapers || Download paper

  21. PAYMENTS, PROMOTION, AND THE PURPLE PILL. (2015). Ridley, David.
    In: Health Economics.
    RePEc:wly:hlthec:v:24:y:2015:i:1:p:86-103.

    Full description at Econpapers || Download paper

  22. Using price–volume agreements to manage pharmaceutical leakage and off-label promotion. (2015). Zaric, Gregory ; Zhang, Hui.
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:16:y:2015:i:7:p:747-761.

    Full description at Econpapers || Download paper

  23. Identifying Industry Margins with Unobserved Price Constraints: Structural Estimation on Pharmaceuticals. (2014). Lasio, Laura ; Dubois, Pierre.
    In: IDEI Working Papers.
    RePEc:ide:wpaper:27918.

    Full description at Econpapers || Download paper

  24. Competitive diffusion of new prescription drugs: The role of pharmaceutical marketing investment. (2014). Ruiz-Conde, Enar ; PEter, ; Wieringa, Jaap E.
    In: Technological Forecasting and Social Change.
    RePEc:eee:tefoso:v:88:y:2014:i:c:p:49-63.

    Full description at Econpapers || Download paper

  25. Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States. (2014). Kanavos, Panos.
    In: Health Policy.
    RePEc:eee:hepoli:v:118:y:2014:i:2:p:229-241.

    Full description at Econpapers || Download paper

  26. Effects of Physician-Directed Pharmaceutical Promotion on Prescription Behaviors: Longitudinal Evidence. (2013). Dave, Dhaval ; Datta, Anusua .
    In: NBER Working Papers.
    RePEc:nbr:nberwo:19592.

    Full description at Econpapers || Download paper

  27. Effects of Pharmaceutical Promotion: A Review and Assessment. (2013). Dave, Dhaval.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:18830.

    Full description at Econpapers || Download paper

  28. Pharmaceutical advertising and Medicare Part D. (2013). Sood, Neeraj ; Lakdawalla, Darius ; Gu, Qian .
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:32:y:2013:i:6:p:1356-1367.

    Full description at Econpapers || Download paper

  29. Competition in the pharmaceutical industry: How do quality differences shape advertising strategies?. (2013). Siotis, Georges ; Ornaghi, Carmine ; de Frutos, Maria-Angeles .
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:32:y:2013:i:1:p:268-285.

    Full description at Econpapers || Download paper

  30. Informing the uninformed: How drug advertising affects check-up visits. (2013). Wendling, Brett ; Hosken, Daniel .
    In: International Journal of Industrial Organization.
    RePEc:eee:indorg:v:31:y:2013:i:2:p:181-194.

    Full description at Econpapers || Download paper

  31. Direct-to-consumer advertising and consumer welfare. (2013). Jayawardhana, Jayani .
    In: International Journal of Industrial Organization.
    RePEc:eee:indorg:v:31:y:2013:i:2:p:164-180.

    Full description at Econpapers || Download paper

  32. Impact of Direct?to?Consumer Advertising on Pharmaceutical Prices and Demand. (2012). Saffer, Henry ; Dave, Dhaval.
    In: Southern Economic Journal.
    RePEc:wly:soecon:v:79:y:2012:i:1:p:97-126.

    Full description at Econpapers || Download paper

  33. Pricing dynamics and product quality: the case of antidepressant drugs. (2012). Rizzo, John ; Chen, Jie.
    In: Empirical Economics.
    RePEc:spr:empeco:v:42:y:2012:i:1:p:279-300.

    Full description at Econpapers || Download paper

  34. Measuring the Informative and Persuasive Roles of Detailing on Prescribing Decisions. (2012). Ching, Andrew ; Ishihara, Masakazu.
    In: Management Science.
    RePEc:inm:ormnsc:v:58:y:2012:i:7:p:1374-1387.

    Full description at Econpapers || Download paper

  35. Direct to Consumer Advertising for Pharmaceuticals: Research Amid the Controversy. (2012). Kleit, Andrew N. ; Bradford, David W..
    In: Chapters.
    RePEc:elg:eechap:14021_31.

    Full description at Econpapers || Download paper

  36. Regulation and competition in the Taiwanese pharmaceutical market under national health insurance. (2012). Hsieh, Chee-Ruey ; Yang, Yea-Huei Kao ; Liu, Ya-Ming .
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:31:y:2012:i:3:p:471-483.

    Full description at Econpapers || Download paper

  37. Determinants of generic entry in the regulated Taiwanese prescription drug market. (2012). Cheng, Jur-Shan ; Liu, Ya-Ming .
    In: Health Policy.
    RePEc:eee:hepoli:v:108:y:2012:i:2:p:228-235.

    Full description at Econpapers || Download paper

  38. Consumer Sovereignty in Healthcare: Fact or Fiction?. (2011). Sirgy, M. ; Yu, Grace ; Lee, Dong-Jin.
    In: Journal of Business Ethics.
    RePEc:kap:jbuset:v:101:y:2011:i:3:p:459-474.

    Full description at Econpapers || Download paper

  39. Determinants of branded prescription medicine prices in OECD countries. (2011). Vandoros, Sotiris ; Kanavos, Panos G..
    In: LSE Research Online Documents on Economics.
    RePEc:ehl:lserod:36351.

    Full description at Econpapers || Download paper

  40. Does Patient Use of Medical Information Affect Physician Practice Incentives to Provide Care?. (2011). Rizzo, John ; Fang, Hai .
    In: Forum for Health Economics & Policy.
    RePEc:bpj:fhecpo:v:14:y:2011:i:2:n:2.

    Full description at Econpapers || Download paper

  41. Modeling the effects of pharmaceutical marketing. (2010). Leeflang, Peter ; Wieringa, Jaap.
    In: Marketing Letters.
    RePEc:kap:mktlet:v:21:y:2010:i:2:p:121-133.

    Full description at Econpapers || Download paper

  42. Marketing and societal welfare: A multiple stakeholder approach. (2010). Matear, Margaret ; Dacin, Peter A..
    In: Journal of Business Research.
    RePEc:eee:jbrese:v:63:y:2010:i:11:p:1173-1178.

    Full description at Econpapers || Download paper

  43. Competition in the Pharmaceutical Industry: How do Quality Differences Shape Advertising Strategies?. (2010). Siotis, Georges ; Ornaghi, Carmine ; de Frutos, Maria-Angeles.
    In: CEPR Discussion Papers.
    RePEc:cpr:ceprdp:8076.

    Full description at Econpapers || Download paper

  44. THE EFFECT OF DIRECT TO CONSUMER TELEVISION ADVERTISING ON THE TIMING OF TREATMENT. (2010). Bradford, W. David ; Kleit, Andrew N. ; Ornstein, Steven ; Nietert, Paul J..
    In: Economic Inquiry.
    RePEc:bla:ecinqu:v:48:y:2010:i:2:p:306-322.

    Full description at Econpapers || Download paper

  45. The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation. (2010). Richards-Shubik, Seth ; Markowitz, Sara ; David, Guy.
    In: American Economic Journal: Economic Policy.
    RePEc:aea:aejpol:v:2:y:2010:i:4:p:1-25.

    Full description at Econpapers || Download paper

  46. The Interplay of Personal Selling and Direct Marketing: An Exploratory Study in the Pharmaceutical Industry. (2009). Hansen, Ann-Kristin .
    In: EconStor Preprints.
    RePEc:zbw:esprep:24826.

    Full description at Econpapers || Download paper

  47. The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation. (2009). Richards-Shubik, Seth ; Markowitz, Sara ; David, Guy.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:14634.

    Full description at Econpapers || Download paper

  48. Direct-to-Consumer Advertising of Prescription Drugs: A Strategic Analysis. (2009). HE, CHUAN ; Amaldoss, Wilfred .
    In: Marketing Science.
    RePEc:inm:ormksc:v:28:y:2009:i:3:p:472-487.

    Full description at Econpapers || Download paper

  49. Heterogeneous Learning and the Targeting of Marketing Communication for New Products. (2009). Manchanda, Puneet ; Narayanan, Sridhar.
    In: Marketing Science.
    RePEc:inm:ormksc:v:28:y:2009:i:3:p:424-441.

    Full description at Econpapers || Download paper

  50. Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation?. (2009). Grasdal, Astrid ; Brekke, Kurt ; Holms, Tor Helge.
    In: European Economic Review.
    RePEc:eee:eecrev:v:53:y:2009:i:2:p:170-185.

    Full description at Econpapers || Download paper

  51. —: A Multicategory Brand Equity Model and Its Application at Allstate. (2008). Shankar, Venkatesh ; Fuller, Matthew ; Azar, Pablo .
    In: Marketing Science.
    RePEc:inm:ormksc:v:27:y:2008:i:4:p:567-584.

    Full description at Econpapers || Download paper

  52. Generalizations on the effectiveness of pharmaceutical promotional expenditures. (2008). , Sara ; Wieringa, Jaap E ; PEter, .
    In: International Journal of Research in Marketing.
    RePEc:eee:ijrema:v:25:y:2008:i:4:p:234-246.

    Full description at Econpapers || Download paper

  53. Pharmaceutical Patents: Incentives for R&D or Marketing?. (2008). Straume, Odd Rune ; Brekke, Kurt.
    In: CESifo Working Paper Series.
    RePEc:ces:ceswps:_2433.

    Full description at Econpapers || Download paper

  54. Advertising, Free-Riding, and Price Differences in the Market for Prescription Drugs. (2008). Linnosmaa, Ismo.
    In: The B.E. Journal of Economic Analysis & Policy.
    RePEc:bpj:bejeap:v:8:y:2008:i:2:n:8.

    Full description at Econpapers || Download paper

  55. Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration. (2007). Ellison, Glenn.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:13069.

    Full description at Econpapers || Download paper

  56. Determinants of outpatient antibiotic consumption in Europe: bacterial resistance and drug prescribers. (2007). Masiero, Giuliano ; Filippini, Massimo ; Ferech, Matus ; Goossens, Herman .
    In: Quaderni della facoltà di Scienze economiche dell'Università di Lugano.
    RePEc:lug:wpaper:0702.

    Full description at Econpapers || Download paper

  57. The Debate on Influencing Doctors Decisions: Are Drug Characteristics the Missing Link?. (2007). Venkataraman, Sriram ; Stremersch, Stefan .
    In: Management Science.
    RePEc:inm:ormnsc:v:53:y:2007:i:11:p:1688-1701.

    Full description at Econpapers || Download paper

  58. The Debate on Influencing Doctors’ Decisions: Are Drug Characteristics the Missing Link?. (2007). Stremersch, Stefan ; Venkataraman, S..
    In: ERIM Report Series Research in Management.
    RePEc:ems:eureri:10520.

    Full description at Econpapers || Download paper

  59. Advertising and generic market entry. (2007). Konigbauer, Ingrid .
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:26:y:2007:i:2:p:286-305.

    Full description at Econpapers || Download paper

  60. Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?. (2007). Grasdal, Astrid ; Brekke, Kurt ; Holms, Tor Helge.
    In: CESifo Working Paper Series.
    RePEc:ces:ceswps:_2059.

    Full description at Econpapers || Download paper

  61. Experts agency problems: evidence from the prescription drug market in Japan. (2007). Iizuka, Toshiaki.
    In: RAND Journal of Economics.
    RePEc:bla:randje:v:38:y:2007:i:3:p:844-862.

    Full description at Econpapers || Download paper

  62. Pharmaceutical promotion and GP prescription behaviour. (2006). Windmeijer, Frank ; de Laat, Eric ; Douven, Rudy ; Mot, Esther .
    In: Health Economics.
    RePEc:wly:hlthec:v:15:y:2006:i:1:p:5-18.

    Full description at Econpapers || Download paper

  63. Dealing with Rising Health Care Costs: The Case of Pharmaceuticals. (2006). Konigbauer, Ingrid .
    In: Munich Dissertations in Economics.
    RePEc:lmu:dissen:5640.

    Full description at Econpapers || Download paper

  64. Direct to consumer advertising in pharmaceutical markets. (2006). Kuhn, Michael ; Brekke, Kurt.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:25:y:2006:i:1:p:102-130.

    Full description at Econpapers || Download paper

  65. Socioeconomic determinants of regional differences in outpatient antibiotic consumption: Evidence from Switzerland. (2006). Masiero, Giuliano ; Filippini, Massimo ; Moschetti, Karine .
    In: Health Policy.
    RePEc:eee:hepoli:v:78:y:2006:i:1:p:77-92.

    Full description at Econpapers || Download paper

  66. The Competitive Effects of Drug Withdrawals. (2005). Rizzo, John ; Cawley, John.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:11223.

    Full description at Econpapers || Download paper

  67. Strategic Pricing and Detailing Behavior in International Markets. (2005). Desiraju, Ramarao ; Chintagunta, Pradeep.
    In: Marketing Science.
    RePEc:inm:ormksc:v:24:y:2005:i:1:p:67-80.

    Full description at Econpapers || Download paper

  68. Direct to Consumer Advertising in Pharmaceutical Markets. (2005). Kuhn, Michael ; Brekke, Kurt.
    In: CESifo Working Paper Series.
    RePEc:ces:ceswps:_1493.

    Full description at Econpapers || Download paper

  69. The Effect of Prescription Drug Advertising on Doctor Visits. (2005). Iizuka, Toshiaki ; Jin, Ginger Zhe.
    In: Journal of Economics & Management Strategy.
    RePEc:bla:jemstr:v:14:y:2005:i:3:p:701-727.

    Full description at Econpapers || Download paper

  70. Are Physicians ÜEasy MarksÝ? Quantifying the Effects of Detailing and Sampling on New Prescriptions. (2004). Mizik, Natalie ; Jacobson, Robert .
    In: Management Science.
    RePEc:inm:ormnsc:v:50:y:2004:i:12:p:1704-1715.

    Full description at Econpapers || Download paper

  71. Persistence in prescriptions of branded drugs. (2004). Horn, Larry Van ; Richard, Oliver .
    In: International Journal of Industrial Organization.
    RePEc:eee:indorg:v:22:y:2004:i:4:p:523-540.

    Full description at Econpapers || Download paper

  72. Diffusion of New Pharmaceutical Drugs in Developing and Developed Nations. (2004). Nair, Harikesh ; Desiraju, Ramarao ; Chintagunta, Pradeep.
    In: Research Papers.
    RePEc:ecl:stabus:1950.

    Full description at Econpapers || Download paper

  73. Pharmaceutical promotion and GP prescription behaviour. (2004). Windmeijer, Frank ; de Laat, Eric ; Douven, Rudy ; Mot, Esther .
    In: CPB Discussion Paper.
    RePEc:cpb:discus:30.

    Full description at Econpapers || Download paper

  74. Competition and substitutability in the Swedish pharmaceuticals market. (2003). Rudholm, Niklas.
    In: Applied Economics.
    RePEc:taf:applec:v:35:y:2003:i:14:p:1609-1617.

    Full description at Econpapers || Download paper

  75. Prescription Drug Advertising and Patient Compliance: A Physician Agency Approach. (2003). Armantier, Olivier ; Namaro, Soiliou Daw.
    In: Department of Economics Working Papers.
    RePEc:nys:sunysb:03-01.

    Full description at Econpapers || Download paper

References

References cited by this document

  1. Anonymous. ‘‘The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V).’’ Archives of Internal Medicine 153, No. 2 (1993): 154–83.
    Paper not yet in RePEc: Add citation now
  2. Avorn, Jerry; Chen, Milton; and Hartley, Robert. ‘‘Scientific vs. Commercial Sources of Influence on the Prescribing Behaviors of Physicians.’’ American Journal of Medicine 73, No. 1 (1982): 4–8. Berndt, Ernst R. ‘‘Causality and Simultaneity between Advertising and Sales.’’ In The Practice of Econometrics: Classic and Contemporary, edited by Ernst R.
    Paper not yet in RePEc: Add citation now
  3. Berndt, pp. 361–448. Reading, Mass.: Addison-Wesley, 1991. Bond, Ronald S., and Lean, David F. ‘‘Sales, Promotion, and Product Differentiation in Two Prescription Drug Markets.’’ Staff Report to the Federal Trade Commission.
    Paper not yet in RePEc: Add citation now
  4. Bowman, Marjorie A. ‘‘The Impact of Drug Company Funding on the Content of Continuing Medical Education.’’ Mobius 6 (1986): 66–69.
    Paper not yet in RePEc: Add citation now
  5. Bowman, Marjorie A., and Pearle, David L. ‘‘Changes in Drug Prescribing Patterns Related to Commercial Company Funding of Continuing Medical Education.’’ Journal of Continuing Education in the Health Professions 8 (1988): 13–20.
    Paper not yet in RePEc: Add citation now
  6. Brodsky, J. Frederick. ‘‘Letter to the Editor.’’ New England Journal of Medicine 327, No. 23 (1992): 1687.
    Paper not yet in RePEc: Add citation now

  7. Comanor, William S. ‘‘The Political Economy of the Pharmaceutical Industry.’’ Journal of Economic Literature 24 (1986): 1178–1217.

  8. Dorfman, Robert, and Steiner, Peter O. ‘‘Optimal Advertising and Optimal Quality. ’’ American Economic Review 44 (1954): 826–36.
    Paper not yet in RePEc: Add citation now
  9. Dustan, Harriet P.; Caplan, Louis R.; Curry, Charles L.; De Leon, Antonio C., Jr.; Douglas, Frank L. et al. ‘‘Report of the Task Force on the Availability of Cardiovascular Drugs to the Medically Indigent.’’ Circulation 85, No. 2 (1992): 849– 60.
    Paper not yet in RePEc: Add citation now
  10. Economic Report of the President, 1994. Washington, D.C.: U.S. Government Printing Office, 1994. Ellison, Sara F.; Cockburn, Iain; Griliches, Zvi; and Hausman, Jerry A. ‘‘Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins.
    Paper not yet in RePEc: Add citation now
  11. Frank, Richard G., and Salkever, David S. ‘‘Pricing, Patent Loss and the Market for Pharmaceuticals.’’ Southern Economic Journal 59, No. 2 (1992): 165–79.
    Paper not yet in RePEc: Add citation now

  12. Grabowski, Henry G., and Vernon, John M. ‘‘Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act.’’ Journal of Law and Economics 35 (1992): 331–50.

  13. Griliches, Zvi, and Cockburn, Iain. ‘‘Generics and New Goods in Pharmaceutical Price Indexes.’’ American Economic Review 84, No. 5 (1994): 1213–32. Hahn, Beth, and Lefkowitz, Doris. Annual Expenses and Sources of Payment for Health Care Services. AHCPR Publication No. 93-0007. National Medical Expenditure Survey Research Findings 14, Agency for Health Care Policy and Research.
    Paper not yet in RePEc: Add citation now

  14. Hurwitz, Mark A., and Caves, Richard E. ‘‘Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals.’’ Journal of Law and Economics 31, No. 2 (1988): 299–320.

  15. Kaplan, Norman M. ‘‘Treatment of Hypertension: Drug Therapy.’’ In Clinical Hypertension, edited by Norman M. Kaplan, pp. 182–267. Baltimore: Williams & Wilkins, 1990.
    Paper not yet in RePEc: Add citation now

  16. Leffler, Keith B. ‘‘Persuasion or Information? The Economics of Prescription Drug Advertising.’’ Journal of Law and Economics 24, No. 1 (1981): 45–74.

  17. Lurie, Nicole; Rich, Eugene C.; Simpson, Deborah E.; Meyer, Jeff; Schiedermayer, David L. et al. ‘‘Pharmaceutical Sales Representatives in Academic Medical Centers: Interaction with Faculty and House Staff.’’ Journal of General Internal Medicine 5, No. 3 (1990): 240–43. McKinney, W. Paul; Schiedermayer, David L.; Lurie, Nicole; Simpson, Deborah E.; Goodman, Jesse L. et al. ‘‘Attitudes of Internal Medicine Faculty and Residents toward Professional Interaction with Pharmaceutical Sales Representatives.
    Paper not yet in RePEc: Add citation now
  18. Nerlove, Marc, and Arrow, Kenneth J. ‘‘Optimal Advertising Policy under Dynamic Conditions.’’ Economica 29 (1962): 129–42.
    Paper not yet in RePEc: Add citation now
  19. Orlowski, James P., and Wateska, Leon. ‘‘The Effects of Pharmaceutical Firm EnThis content downloaded from 144.076.058.107 on November 02, 2016 12:47:02 PM All use subject to University of Chicago Press Terms and Conditions (http://www.journals.uchicago.edu/t-and-c). the journal of law and economics ticements on Physician Prescribing Patterns: There’s No Such Thing as a Free Lunch.’’ Chest 102, No. 1 (1992): 270–73.
    Paper not yet in RePEc: Add citation now
  20. Physicians Desk Reference. Montvale, N.J.: Medical Economics, Inc., 1993.
    Paper not yet in RePEc: Add citation now

  21. Rizzo, John A., and Zeckhauser, Richard J. ‘‘Advertising and Entry: The Case of Physician Services.’’ Journal of Political Economy 98, No. 3 (1990): 476–500.

  22. Rizzo, John A., and Zeckhauser, Richard J. ‘‘Advertising and the Price, Quantity, and Quality of Primary Care Physician Services.’’ Journal of Human Resources 27, No. 3 (1992): 381–421.

  23. Rockville, Md.: Public Health Service, 1992.
    Paper not yet in RePEc: Add citation now
  24. Scherer, F. Michael. ‘‘Pricing, Profits, and Technological Progress in the Pharmaceutical Industry.’’ Journal of Economic Perspectives 7, No. 3 (1993): 97–115.
    Paper not yet in RePEc: Add citation now

  25. Telser, Lester G., et al. ‘‘The Theory of Supply with Applications to the Ethical Pharmaceutical Industry.’’ Journal of Law and Economics 18, No. 2 (1975): 449–78.

  26. Temin, Peter. Taking Your Medicine: Drug Regulation in the United States. Cambridge, Mass.: Harvard University Press, 1980.
    Paper not yet in RePEc: Add citation now
  27. This content downloaded from 144.076.058.107 on November 02, 2016 12:47:02 PM All use subject to University of Chicago Press Terms and Conditions (http://www.journals.uchicago.edu/t-and-c).
    Paper not yet in RePEc: Add citation now
  28. This content downloaded from 144.076.058.107 on November 02, 2016 12:47:02 PM All use subject to University of Chicago Press Terms and Conditions (http://www.journals.uchicago.edu/t-and-c). advertising of pharmaceuticals 115 Interactions with Drug Companies.’’ Journal of the American Medical Association 271, No. 9 (1994): 684–89.
    Paper not yet in RePEc: Add citation now
  29. U.S. Senate. Subcommittee on Antitrust and Monopoly. Report of the Study of Administered Prices in the Drug Industry. 87th Cong., 1st Sess., Washington, D.C., 1961.
    Paper not yet in RePEc: Add citation now

  30. Vernon, John M. ‘‘Concentration, Promotion, and Market Share Stability in the Pharmaceutical Industry.’’ Journal of Industrial Economics 19, No. 3 (1971): 246–66.

  31. Washington, D.C.: Federal Trade Commission, 1977.
    Paper not yet in RePEc: Add citation now
  32. Waud, Douglas R. (1992). ‘‘Pharmaceutical Promotions—A Free Lunch?’’ New England Journal of Medicine 327, No. 5 (1992): 351–53.
    Paper not yet in RePEc: Add citation now

Cocites

Documents in RePEc which have cited the same bibliography

  1. INTELLECTUAL PROPERTY APPROPRIATION STRATEGY AND ITS IMPACT ON INNOVATION PERFORMANCE. (2016). Hussain, Sairah ; Terziovski, Mile.
    In: International Journal of Innovation Management (ijim).
    RePEc:wsi:ijimxx:v:20:y:2016:i:02:n:s136391961650016x.

    Full description at Econpapers || Download paper

  2. When do firms change technology-sourcing vehicles? The role of poor innovative performance and financial slack. (2016). Zajac, Edward J ; Lungeanu, Razvan ; Stern, Ithai.
    In: Strategic Management Journal.
    RePEc:bla:stratm:v:37:y:2016:i:5:p:855-869.

    Full description at Econpapers || Download paper

  3. Regulation of the Pharmaceutical-Biotechnology Industry. (2014). Keuffel, Eric ; Danzon, Patricia M..
    In: NBER Chapters.
    RePEc:nbr:nberch:12572.

    Full description at Econpapers || Download paper

  4. Technological regimes and demand structure in the evolution of the pharmaceutical industry. (2012). Pezzoni, Michele ; Orsenigo, Luigi ; Garavaglia, Christian ; Malerba, Franco.
    In: Journal of Evolutionary Economics.
    RePEc:spr:joevec:v:22:y:2012:i:4:p:677-709.

    Full description at Econpapers || Download paper

  5. Pricing dynamics and product quality: the case of antidepressant drugs. (2012). Rizzo, John ; Chen, Jie.
    In: Empirical Economics.
    RePEc:spr:empeco:v:42:y:2012:i:1:p:279-300.

    Full description at Econpapers || Download paper

  6. Brand-Name and Generic Drug Pricing in a Regulated Environment: Findings from Canada. (2012). Xu, Kuan ; Sketris, Ingrid ; Ren, Zhe .
    In: Working Papers.
    RePEc:dal:wpaper:daleconwp2011-04.

    Full description at Econpapers || Download paper

  7. .

    Full description at Econpapers || Download paper

  8. Colleagues, Where Is the Market Failure? Economists on the FDA. (2008). Klein, Daniel.
    In: Econ Journal Watch.
    RePEc:ejw:journl:v:5:y:2008:i:3:p:316-348.

    Full description at Econpapers || Download paper

  9. Generic entry, price competition, and market segmentation in the prescription drug market. (2008). Regan, Tracy.
    In: International Journal of Industrial Organization.
    RePEc:eee:indorg:v:26:y:2008:i:4:p:930-948.

    Full description at Econpapers || Download paper

  10. Multiple Interfaces of Big Pharma and the Change of Global Health Governance in the Face of HIV/AIDS. (2006). Wogart, Jan Peter.
    In: GIGA Working Papers.
    RePEc:zbw:gigawp:24.

    Full description at Econpapers || Download paper

  11. Product-line expansion and resource cannibalization. (2005). Roberts, Peter W. ; McEvily, Susan.
    In: Journal of Economic Behavior & Organization.
    RePEc:eee:jeborg:v:57:y:2005:i:1:p:49-70.

    Full description at Econpapers || Download paper

  12. Secrecy in the Shadow of Patenting: Firms Use of Continuation Patents, 1975-1994. (2004). Graham, Stuart.
    In: Levine's Working Paper Archive.
    RePEc:cla:levarc:228400000000000035.

    Full description at Econpapers || Download paper

  13. Innovation and firm-level persistent profitability: a Schumpeterian framework. (2001). Roberts, Peter W.
    In: Managerial and Decision Economics.
    RePEc:wly:mgtdec:v:22:y:2001:i:4-5:p:239-250.

    Full description at Econpapers || Download paper

  14. Innovation and Merger Decisions in the Pharmaceutical Industry. (2001). Morgan, Eleanor .
    In: Review of Industrial Organization.
    RePEc:kap:revind:v:19:y:2001:i:2:p:181-197.

    Full description at Econpapers || Download paper

  15. Integration problems and turnaround strategies in a cross-border merger A clinical examination of the Pharmacia-Upjohn merger. (2000). Nail, Lance ; Belcher, Terry.
    In: International Review of Financial Analysis.
    RePEc:eee:finana:v:9:y:2000:i:2:p:219-234.

    Full description at Econpapers || Download paper

  16. Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs.. (1999). Rizzo, John.
    In: Journal of Law and Economics.
    RePEc:ucp:jlawec:v:42:y:1999:i:1:p:89-116.

    Full description at Econpapers || Download paper

  17. Le rôle des prix dans la régulation du secteur pharmaceutique. (1998). Jacobzone, Stephane .
    In: Économie et Statistique.
    RePEc:prs:ecstat:estat_0336-1454_1998_num_312_1_2617.

    Full description at Econpapers || Download paper

  18. Le marché pharmaceutique français : la prépondérance des produits-phares. (1998). Rupprecht, Frederic ; Iung, Nicolas .
    In: Économie et Statistique.
    RePEc:prs:ecstat:estat_0336-1454_1998_num_312_1_2616.

    Full description at Econpapers || Download paper

  19. Products Liability and Prescription Drug Prices in Canada and the United States.. (1997). Manning, Richard L.
    In: Journal of Law and Economics.
    RePEc:ucp:jlawec:v:40:y:1997:i:1:p:203-43.

    Full description at Econpapers || Download paper

  20. Present at the biotechnological revolution: transformation of technological identity for a large incumbent pharmaceutical firm. (1997). Zucker, Lynne ; Darby, Michael.
    In: Research Policy.
    RePEc:eee:respol:v:26:y:1997:i:4-5:p:429-446.

    Full description at Econpapers || Download paper

  21. Pharmaceutical cost containment and innovation in the United States. (1997). Kane, Nancy M..
    In: Health Policy.
    RePEc:eee:hepoli:v:41:y:1997:i:sup1:p:s71-s89.

    Full description at Econpapers || Download paper

  22. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada. (1997). Vandergrift, Michael ; Kanavos, Panos.
    In: Health Policy.
    RePEc:eee:hepoli:v:41:y:1997:i:3:p:241-260.

    Full description at Econpapers || Download paper

  23. The optimal organization of research: evidence from eight case studies of pharmaceutical firms. (1996). Tapon, Francis ; Cadsby, Charles.
    In: Journal of Economic Behavior & Organization.
    RePEc:eee:jeborg:v:31:y:1996:i:3:p:381-399.

    Full description at Econpapers || Download paper

  24. Lessons from the United Statess antitrust history. (1996). Mueller, Dennis.
    In: International Journal of Industrial Organization.
    RePEc:eee:indorg:v:14:y:1996:i:4:p:415-445.

    Full description at Econpapers || Download paper

  25. NGOs and Environmental Public Goods: Institutional Alternatives to Property Rights. (1996). Meyer, Carrie A.
    In: Development and Change.
    RePEc:bla:devchg:v:27:y:1996:i:3:p:453-474.

    Full description at Econpapers || Download paper

  26. Present at the Revolution: Transformation of Technical Identity for a Large Incumbent Pharmaceutical Firm After the Biotechnological Breakthrough. (1995). Zucker, Lynne ; Darby, Michael.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:5243.

    Full description at Econpapers || Download paper

  27. Scale, Scope and Spillovers: The Determinants of Research Productivity in the Pharmaceutical Industry. (1993). Henderson, Rebecca ; Cockburn, Iain.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:4466.

    Full description at Econpapers || Download paper

  28. Scale, scope and spillovers : the determinants of research productivity in ethical drug discovery. (1993). Henderson, Rebecca ; Cockburn, Iain.
    In: Working papers.
    RePEc:mit:sloanp:2499.

    Full description at Econpapers || Download paper

  29. Abstract. (1993). Dierickx, Ingemar ; Cool, Karel.
    In: Strategic Management Journal.
    RePEc:bla:stratm:v:14:y:1993:i:1:p:47-59.

    Full description at Econpapers || Download paper

  30. Pricing, Profits, and Technological Progress in the Pharmaceutical Industry. (1993). Scherer, F M.
    In: Journal of Economic Perspectives.
    RePEc:aea:jecper:v:7:y:1993:i:3:p:97-115.

    Full description at Econpapers || Download paper

  31. Réglementation des prix et formes de la concurrence dans lindustrie pharmaceutique. (1988). le Pen, Claude.
    In: Revue Économique.
    RePEc:prs:reveco:reco_0035-2764_1988_num_39_6_409118.

    Full description at Econpapers || Download paper

Coauthors

Authors registered in RePEc who have wrote about the same topic

Report date: 2025-03-06 15:43:30 || Missing content? Let us know

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated October, 6 2023. Contact: CitEc Team.